From £200

Macular Degeneration Treatment - London

Monitor your macular degeneration symptoms with our private clinic.

Top London Surgeon

Trusted and highly recommended locally.

Local Consultation

Honest advice with no obligation to proceed.

Advanced Technology

The safest laser treatments available.

0% Finance

Interest-free monthly payments.

Macular degeneration (AMD)

Macular degeneration (AMD) is a common age-related eye disease which affects the clarity of your central vision. The incidence of macular degeneration increases with age, and about three people per 1000 over the age of 50 will develop macular degeneration.

Macular degeneration is categorised as an “age-related” eye condition meaning that it occurs mainly in older people.

Diagnosis and treatment for Macular degeneration

Understanding Macular Degeneration

The macula is the area of the retina that’s responsible for seeing clearly in the centre of your vision.

If you are experiencing blurriness, distortion or blank spots in your central vision, our ophthalmologists can carry out comprehensive eye assessments to check the condition of your eyes and diagnose the type of macular degeneration you are experiencing.

There are two types of macular degeneration conditions:

Dry age-related macular degeneration:

Macular degeneration
treatment

Although there is no definite treatment to reverse any current symptoms of macular degeneration, our ophthalmologist can help prevent or slow the progression of the disease.

After diagnosing your condition, your specialist will begin the treatment process.

If you are diagnosed with wet macular degeneration, your specialist will repeat Anti-VEGF and/or other injections to preserve and stabilise your vision. This treatment will require regular check-ups and monitoring of your vision.

Dry macular degeneration requires frequent monitoring and check-ups of the eyes. Dry macular degeneration is a less damaging condition for your eyes and does not require injections for treatment.

AMD Treatment Options: Tests, Visits, and Red Flags

Macular degeneration affects central vision, but the right plan can stabilise sight and protect day-to-day independence. Use the table below to compare care for dry AMD, geographic atrophy, and wet AMD including key tests, first-line treatments, follow-up timing, home monitoring, and the symptoms that need urgent same-day review.

Macular Degeneration Treatments & Follow-Up at a Glance

Compare care pathways for dry, geographic atrophy, and wet AMD: tests, first-line treatments, monitoring, and when it’s urgent.

AMD Type / Stage Typical Signs Core Tests First-Line Treatment In-Clinic Options Home Monitoring Follow-Up When Urgent
Dry AMD — Early/Intermediate Mild blur, difficulty in low light, drusen on exam Dilated exam, OCT, colour fundus photos Lifestyle + nutrition (AREDS2 where appropriate), control cardiovascular risks, stop smoking Low-vision advice if needed; blue-light/contrast optimisation Amsler grid or home apps; note new distortion/blur 6–12 monthly, sooner if changes Sudden distortion or central blur → urgent check for wet AMD
Geographic Atrophy (Advanced Dry) Patchy central blind spots, reading difficulty; slow progression OCT, fundus autofluorescence (FAF), photos to map atrophy Vision optimisation, task lighting, low-vision aids; consider GA-targeted therapy if suitable GA therapies (specialist injections where indicated); rehab and device training Reading aids, high-contrast settings, home grid to detect new distortion 3–6 monthly monitoring of atrophy growth New sudden distortion/blur → urgent to exclude conversion to wet AMD
Wet (Neovascular) AMD Sudden central blur, straight lines look wavy (metamorphopsia) OCT macula, OCT-A/fluorescein angiography as needed Intravitreal anti-VEGF injections (loading phase then maintenance) Treat-and-extend or PRN regimens; switch agents if suboptimal response Daily self-check (Amsler); report new distortion immediately Monthly during loading, then 4–12 weekly per response Emergency: sudden distortion, dark patch, or rapid vision drop
Risk Reduction (All Stages) Family history, age 55+, smoking, high BMI, hypertension Baseline OCT/photos; lifestyle review Stop smoking, heart-healthy diet (leafy greens, fish), manage BP/cholesterol, sunglasses/UV protection Nutrition counselling; coordinate GP/cardiovascular care Amsler grid weekly; recognise red flags Annual check if low risk; more often with changes Any new distortion or central blur → urgent assessment
Low-Vision Support Reading difficulty, contrast loss, glare sensitivity Functional vision assessment, glare/contrast testing Task lighting, magnifiers, electronic readers, contrast settings Referral to low-vision services; device training Practice with aids; home environment optimisation As needed to refine aids and goals Rapid change in vision → prompt review
This overview is informational. Treatment choices depend on detailed imaging and clinical findings. If you notice new distortion, a dark patch, or sudden central blur, seek urgent same-day assessment.

Our Most Important FAQs For Macular Degeneration

Thinking about Macular Degeneration? It’s natural to have questions about what it can do for you. From vision improvements to advanced safety features, here are the key benefits and facts that will help you understand why more people than ever are choosing laser vision correction.

Wet age-related macular degeneration can cause a sudden change in vision loss and is a long-lasting eye condition. Vision loss is caused by abnormal blood vessels growing into the macula.

Anti-VEGF injections are used for patients who have been diagnosed with wet macular degeneration (WMD). Anti-VEGF injections are a frequent treatment to stabilise your vision and prevent further vision loss. Anti-VEGF is a protein which prevents the growth of new blood vessels in the eye and controls the eye fluid.

You may be experiencing the following symptoms from macular degeneration:

  • Reduced and/or distorted areas in your central vision
  • Difficulty with close-up work such as reading and driving.
  • Difficulty seeing in low light environments
  • Blank or dark spots in your field of vision
  • Straight lines looking wavy or crooked
  • Reduced intensity of brightness and colours
If you are experiencing any of the symptoms above, please contact0208 445 8877for a private eye assessment and consultation with our ophthalmologist.

The onset of macular degeneration usually occurs from 50 to 60 years of age. During this period, you may start to experience early warning signs of macular degeneration. The exact cause of macular degeneration is unknown; however, lifestyle choices such as smoking, poor diet, high blood pressure and a family history of macular degeneration can put you at risk of the condition. It is always best to have routine eye checks with your local opticians and our ophthalmologist to monitor any early macular degeneration symptoms.

Macular degeneration is very rare in young people since it is an age-related eye disease. Usually, young adults who develop macular degeneration have the condition due to an inherited abnormality.

Our technicians carry out comprehensive eye assessments, giving a clear view of all the layers of the retina, to allow our ophthalmologist to give you an accurate diagnosis in your private consultation. These eye assessments also allow for careful monitoring of the condition and for treatment planning. If you are concerned about your vision, please call 0208 445 8877 for more information about a consultation with our ophthalmologist.

Overall, patients who use anti-VEGF injections as treatment for macular degeneration see an improvement in their vision. As wet macular degeneration is a serious eye condition that increasingly causes vision loss, treatment is always advised to prevent any risk of blindness.

Dry age-related macular degeneration is a common eye disease that progressively causes vision loss over a longer period of time. This is because the tissue in the macula thins and causes a reduction and “wearing out” of the retinal cells.

Anti-VEGF injections are very successful in treating wet macular degeneration (WMD). Anti-VEGF injections are frequently administered by our ophthalmologist to stabilise your vision and to preserve the central vision.

 

Request An Appointment

Fill in your details, and start your journey towards clearer vision!


Search My-iClinic

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Meera Radia

Consultant Ophthalmologist

SPECIALTIES

EDUCATION

  • FRCOphth – Fellow of the Royal College of Ophthalmologists
  • CertLRS – Certificate in Laser and Refractive Surgery, Royal College of Ophthalmologists
  • MBA – awarded a fully funded academic scholarship for postgraduate business studies
  • MBBS (Hons)
  • BSc (Hons)
  • Ophthalmology Specialist Training – North Thames Deanery
  • Advanced Fellowship Training in Medical Retina, Uveitis and Cataract Surgery – Moorfields Eye Hospital, London

RESEARCH

Meera has published and presented research across medical retina, artificial intelligence, ophthalmic imaging, cataract and digital eye care.
Her research has included work on deep-learning systems for the detection of retinopathy of prematurity, artificial-intelligence classification of retinal images, surgical outcomes in macular hole surgery, ophthalmic simulation and the availability of image datasets for anterior-segment artificial intelligence research.
Selected publications include work in the Journal of Cataract & Refractive SurgeryThe Lancet Digital HealthGraefe’s Archive for Clinical and Experimental OphthalmologyInvestigative Ophthalmology & Visual Science and the British Journal of Hospital Medicine.
She was also part of a team awarded a £70,000 Bayer Ophthalmology Research Award for research into artificial intelligence in retinopathy of prematurity.

AFFILIATIONS

  • Royal College of Ophthalmologists
  • European Society of Retina Specialists (EURETINA)
  • European Society of Cataract and Refractive Surgeons (ESCRS)
  • UK & Ireland Society of Cataract and Refractive Surgeons
  • International Ocular Inflammation Society
  • Chair and Lead, North West London Uveitis Network
  • Royal College of Ophthalmologists CESR Pathway Assessor
  • Former Associate College Tutor, Western Eye Hospital, Imperial College Healthcare NHS Trust
  • NHS England Clinical Entrepreneur Programme Fellow
  • Former elected Public Governor, Royal Free London NHS Foundation Trust

Harry Orlans

Consultant and Surgeon

SPECIALTIES

EDUCATION

– BA (Hons) Physiology & Neuroscience, 1st Class, University of Cambridge (2007)
 
– BM BCh Batchelor of Medicine & Batchelor of Surgery with Distinction, University of Oxford (2010)
 
– MA (Cantab), University of Cambridge (2011)
 
– The Crombie Medal, Royal College of Ophthalmologists (2011)
 
– FRCOphth, Royal College of Ophthalmologists (2017)
 
– DPhil (PhD), University of Oxford (2019)
 
– Fellowship in Vitreoretinal Surgery, St Thomas’ Hospital, London (2020-2021)
 
– Fellowship in Vitreoretinal Surgery, Moorfields Eye Hospital, London (2022-2023)
 
– Fellowship in Medical Retina, Moorfields Eye Hospital, London (2023)
 
– AFHEA, Associate Fellow of the Higher Education Academy (2025)
 

LATEST RESEARCH

– MRC/Fight for Sight Clinical Training Research Fellowship (2015)
 
– The Founders Cup and Medal, Oxford Ophthalmological Congress (2018)
 
– MRC Developmental Pathway Funding Scheme (2020)
 
– The Ruskell Medal for Research, The Worshipful Company of Spectacle Makers (2021)
 
Zheng Q, Orlans HO, Staurenghi F, McClements ME, MacLaren RE. Design and Validation of Mirtron-Mediated RNA Interference for Gene Therapy Therapy Methods Mol Biol. 2026; 3023: 195-206.
 
Orlans HO, Yazdouni S, Williamson TH, Wong RS, Laidlaw DAH. A novel post-operative drop regimen reduces risk of ocular hypertension following pars plana vitrectomy. Ophthalmologica. 2023; 246(1):32-38.
 
Azad A, Laidlaw DAH, Orlans HO. Using QR smartphone technology to improve patient communication and information distribution. Eye 2022;26(6):1321-1322.
 
Orlans HO, McClements ME, Barnard AR, et al. Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. Nat Commun 2021;12:4934.
 
Corazza P, D’Alterio FM, Kabbani J, Alum MMR, Mercuri S, Orlans HO, Younis S. Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmol 2021;21:300.
 
Xue K, Jolly JK, Barnard AR… Orlans HO et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med 2018;24:1507–1512.

AFFILIATIONS

Fellowships and Memberships in Professional Societies
 
– Fellow of the Royal College of Ophthalmologists
 
– Member of the British & Eire Association of Vitreoretinal Surgeons (BEAVRS)
 
– Member of the European Society of Retinal Specialists (Euretina)
 
– Associate Fellow of the Higher Education Academy (Advance HE)